- Home
- SYBT vs IMVT Comparison
SYBT vs IMVT Comparison
Compare SYBT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- IMVT
- Stock Information
- Founded
- SYBT 1904
- IMVT 2018
- Country
- SYBT United States
- IMVT United States
- Employees
- SYBT N/A
- IMVT N/A
- Industry
- SYBT Major Banks
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYBT Finance
- IMVT Health Care
- Exchange
- SYBT Nasdaq
- IMVT Nasdaq
- Market Cap
- SYBT 2.3B
- IMVT 2.7B
- IPO Year
- SYBT N/A
- IMVT N/A
- Fundamental
- Price
- SYBT $80.71
- IMVT $14.69
- Analyst Decision
- SYBT Hold
- IMVT Buy
- Analyst Count
- SYBT 3
- IMVT 11
- Target Price
- SYBT $83.67
- IMVT $35.88
- AVG Volume (30 Days)
- SYBT 99.3K
- IMVT 1.1M
- Earning Date
- SYBT 10-22-2025
- IMVT 08-11-2025
- Dividend Yield
- SYBT 1.53%
- IMVT N/A
- EPS Growth
- SYBT 22.18
- IMVT N/A
- EPS
- SYBT 4.35
- IMVT N/A
- Revenue
- SYBT $364,546,000.00
- IMVT N/A
- Revenue This Year
- SYBT $16.83
- IMVT N/A
- Revenue Next Year
- SYBT $5.12
- IMVT N/A
- P/E Ratio
- SYBT $18.64
- IMVT N/A
- Revenue Growth
- SYBT 11.32
- IMVT N/A
- 52 Week Low
- SYBT $56.35
- IMVT $12.72
- 52 Week High
- SYBT $83.83
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- SYBT 58.68
- IMVT 39.36
- Support Level
- SYBT $74.24
- IMVT $14.80
- Resistance Level
- SYBT $83.83
- IMVT $15.39
- Average True Range (ATR)
- SYBT 2.10
- IMVT 0.51
- MACD
- SYBT 0.71
- IMVT 0.00
- Stochastic Oscillator
- SYBT 70.23
- IMVT 12.87
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.